United Therapeutics Launches Accelerated Buyback for Remaining $2B Authorization
UTHR sits 31% above its 52-week low of $375.61.
Summary
United Therapeutics has entered into an accelerated share repurchase agreement to execute the remainder of its $2.0 billion buyback authorization. This follows the initial $1.5 billion accelerated program completed earlier this year, as noted in the Q2 report. The move signals management's confidence in the stock and provides immediate support to the share price. With a market cap near $21 billion, the remaining buyback represents a meaningful return of capital. Investors will watch for the final settlement terms and any impact on earnings per share.
At the time of this announcement, UTHR was trading at $493.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.9B. The 52-week trading range was $375.61 to $609.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.